ALLOEarnings•globenewswire•
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
Sentiment:Negative (10)
Summary
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 13, 2025 by globenewswire